Intracranial Pressure (ICP) Management Guideline

🧠 Intracranial Pressure (ICP) Management Guideline

Tiered ICP Management Protocol with Osmotherapy Dosing Calculator

Reviewed by the DosePilot Medical Team · Last medically reviewed: June 2026

—
Tier 0 — Baseline Neuroprotective Measures
🛏 Head of Bed & Positioning

• Elevate head of bed 30° (reduces ICP by improving venous drainage)

• Maintain head midline position — avoid neck flexion/rotation (prevents jugular venous compression)

• Loosen cervical collar if present

🌡 Temperature Control

• Target normothermia (36–37.5°C)

• Actively prevent and treat fever (each 1°C above 37°C increases cerebral metabolic demand by ~8%)

• Acetaminophen 1g IV q6h + cooling blanket/device as needed

💨 Ventilation & Oxygenation

• Target PaCO₂ 35–40 mmHg (low-normal eucapnia)

• Avoid hypoxia: SpO₂ ≥ 94%, PaO₂ ≥ 60 mmHg

• Avoid high PEEP (>12 cmH₂O) unless required for oxygenation — may impede cerebral venous return

⚠ Caution: Avoid hyperventilation (PaCO₂ <35) in Tier 0. Cerebral vasoconstriction reduces CBF and may worsen ischemia, especially within the first 24 hours post-injury.
💤 Sedation & Analgesia

• Propofol 20–50 mcg/kg/min OR Midazolam 0.02–0.1 mg/kg/hr for sedation

• Fentanyl 0.5–2 mcg/kg/hr OR Remifentanil for analgesia

• Target RASS −1 to −2 initially (deepen to −3 to −5 in Tier 1 if needed)

⚠ Propofol: Max <5 mg/kg/hr. Monitor for propofol infusion syndrome (PRIS) with prolonged use >48h — check triglycerides, CK, lactate. Contraindicated in egg/soy allergy.
❤ Hemodynamic Targets (CPP)

• Target CPP 60–70 mmHg (CPP = MAP − ICP)

• If ICP not monitored: target MAP ≥ 80 mmHg (ACS TBI 2024)

• Avoid CPP >70 mmHg aggressively — increases ARDS risk (BTF Level II)

• Avoid hypotension (SBP <90 mmHg) — a single episode doubles mortality

• Use norepinephrine as first-line vasopressor if MAP support is needed

⚡ Seizure Prophylaxis

• Levetiracetam 500–1000 mg IV q12h (preferred) OR Phenytoin (loading 20 mg/kg)

• Recommended for 7 days post-TBI to prevent early post-traumatic seizures

• Consider continuous EEG if comatose — up to 1/3 of patients have non-convulsive seizures

📉 Glucose Control & Nutrition

• Target glucose 140–180 mg/dL — avoid tight glycemic control (<110) in TBI (increases metabolic distress)

• Avoid hyperglycemia >200 mg/dL

• Initiate early enteral nutrition within 24–48 hours if possible

💧 Fluid & Hemoglobin Targets

• Maintain euvolemia with isotonic crystalloid (0.9% NaCl or balanced solution)

• Avoid hypotonic fluids (D5W, 0.45% NaCl) — worsens cerebral edema

• Hemoglobin transfusion threshold: ≥ 7 g/dL (ACS TBI 2024; liberal transfusion has not improved neurological outcomes)

📊 ICP Monitoring

• EVD (External Ventricular Drain): gold standard — allows both monitoring and therapeutic CSF drainage

• Intraparenchymal monitor: alternative when EVD placement not feasible

• Indications: GCS 3–8 with abnormal CT, or normal CT with ≥2 of: age >40, motor posturing, SBP <90

• Treatment threshold: ICP >20–22 mmHg

Tier 1 — First-Line ICP-Lowering Therapies
💧 CSF Drainage via EVD

• If EVD in place: open to drain at 10–15 cmH₂O for intermittent or continuous drainage

• Monitor CSF output (typically drain 5–10 mL when ICP rises above threshold)

• Watch for ventriculostomy-related infection (incidence 5–15%)

⚠ Caution: Risk of ventriculitis, hemorrhage during placement, over-drainage leading to slit ventricle. Do not drain against collapsed ventricles.
💤 Deepen Sedation

• Increase sedation depth to RASS −3 to −5 (unarousable)

• Reduces cerebral metabolic rate and thus ICP

💊 Osmotherapy Select Agent Below

Select an osmotherapy agent to view dosing, contraindications, and monitoring:

Mannitol 20% — 0.25–1 g/kg IV bolus over 15–20 min

Onset: 15–30 min | Duration: 1.5–6 hours | Repeat: q4–6h PRN

Osmotic reflection coefficient: 0.9 (partial BBB permeability → risk of rebound ICP with prolonged use)

Practical tip: Usually stocked as 12.5g bottles. 50g (250 mL of 20%) is a reasonable dose for CNS emergency en route to OR.

⚠ Contraindications & Cautions:
• Serum osmolality ≥320 mOsm/kg — risk of AKI, CNS toxicity (mandatory check before each dose)
• Hypovolemia / Hypotension — osmotic diuresis worsens dehydration; ensure euvolemia first
• Active intracranial hemorrhage (uncontrolled) — reduced viscosity may increase bleeding
• Compromised BBB — mannitol leaks into parenchyma causing rebound edema
• Anuria / severe renal failure — accumulation risk (half-life extends to 6–48h)
• Decompensated heart failure — initial volume expansion may precipitate pulmonary edema
• Known hypersensitivity to mannitol
✅ Monitoring:
• Serum osmolality q4–6h (hold if ≥320 mOsm/kg)
• Serum Na⁺, K⁺, BUN/Cr, I&O (aggressive diuresis → replace losses)
• Osmol gap: if >20 mOsm/kg, use with caution; if >55, contraindicated
• Avoid abrupt discontinuation after prolonged use — taper to prevent rebound ICP
3% NaCl — 150–250 mL IV bolus over 10–20 min (or 2–5 mL/kg)

Onset: Minutes | Duration: 2–6 hours | Repeat: q4–6h PRN

Osmotic reflection coefficient: 1.0 (does not cross intact BBB → no rebound effect)

Advantage over mannitol: No diuresis → maintains hemodynamic stability and CPP. Can be given peripherally.

Continuous infusion option: 0.5–1 mL/kg/hr, titrate to target Na⁺ 145–155 mEq/L.

⚠ Contraindications & Cautions:
• Serum Na⁺ ≥155–160 mEq/L — risk of central pontine myelinolysis, worsened hypernatremia
• Decompensated CHF — volume expansion may precipitate pulmonary edema
• Severe hyperchloremic metabolic acidosis — high chloride load exacerbates acidosis
• Hyponatremia correction >8–10 mEq/L/24h — risk of osmotic demyelination syndrome (ODS)
• Peripheral line caution: Safe for bolus at 3% concentration, but monitor IV site for phlebitis/extravasation
✅ Monitoring:
• Serum Na⁺ q4–6h (target 145–155 mEq/L; do not exceed 160)
• Serum Cl⁻, osmolality, fluid balance
• If on continuous infusion: taper gradually when discontinuing — do not abruptly stop
• Monitor IV site if peripheral — extravasation of HTS can cause tissue necrosis
23.4% NaCl — 30 mL IV bolus over 10–20 min via central line ONLY

Onset: Minutes | Duration: 2–6 hours | Repeat: q4–6h PRN

Na⁺ content: 4,004 mEq/L (30 mL = ~120 mEq Na⁺)

Use: Reserved for acute herniation or refractory ICP elevation unresponsive to 3% NaCl or mannitol.

⚠ Contraindications & Cautions:
• MUST use central venous catheter — peripheral administration causes severe phlebitis and tissue necrosis
• Serum Na⁺ ≥160 mEq/L
• Decompensated CHF / Pulmonary edema
• Rapid administration (<10 min) — risk of hypotension, bradycardia
• All contraindications of 3% NaCl also apply
✅ Monitoring:
• Same as 3% NaCl + central line patency check
• Serum Na⁺ q2–4h after each dose (expect larger Na⁺ shifts)
• Continuous cardiac monitoring during infusion
Glycerol 10% — 0.5–1 g/kg IV over 30–60 min (or PO in non-emergent)

Onset: 30–60 min | Duration: 4–6 hours | Repeat: q6–8h

Route: IV (10% solution) or PO (50% solution, 1–1.5 g/kg mixed with juice)

Characteristics: Metabolized by the liver, provides caloric value (~4.3 kcal/g). Milder osmotic effect compared to mannitol/HTS. More commonly used in Asia/Europe.

⚠ Contraindications & Cautions:
• Diabetes mellitus (uncontrolled) — metabolized to glucose; can cause severe hyperglycemia
• Hepatic failure — hepatic metabolism impaired; accumulation risk
• Renal failure — reduced excretion
• Dehydration / Hypovolemia
• Hemolytic conditions — IV glycerol can cause hemolysis if administered too rapidly
• Hereditary fructose intolerance
✅ Monitoring:
• Blood glucose q2–4h (especially in diabetics)
• Serum osmolality, renal function
• Signs of hemolysis if IV route used (hemoglobinuria, LDH, haptoglobin)
Tier 2 — Second-Line Therapies
💨 Mild Hyperventilation

• Target PaCO₂ 32–35 mmHg (temporizing measure only)

• Reduces ICP by cerebral vasoconstriction → decreased cerebral blood volume

• Effect begins within seconds, peaks at 15–30 min

• Duration: Use only as a bridge — effectiveness wanes after 4–6 hours due to CSF bicarbonate compensation

⚠ Critical Warnings:
• Avoid PaCO₂ <30 mmHg — aggressive hyperventilation worsens cerebral ischemia
• Avoid within 24 hours post-injury — CBF already critically reduced in acute phase (BTF Level III)
• If used, monitor SjvO₂ (jugular venous O₂ sat, target >55%) or PbtO₂ (>20 mmHg) to detect cerebral ischemia
• Do NOT use prophylactically — only for acute ICP elevation refractory to Tier 1
📈 MAP Challenge (Autoregulation Assessment)

• Purpose: Assess static pressure autoregulation (sPAR) status to guide CPP management

• Method: Increase MAP/CPP by 10 mmHg for 20 min using fluid bolus and/or norepinephrine

• Interpretation:

 → Intact sPAR: ICP decreases (cerebral vasoconstriction) → maintain the elevated MAP/CPP

 → Impaired sPAR: ICP increases (passive vasodilation) → stop vasopressor, return MAP to baseline

✅ During MAP Challenge:
• Do NOT adjust osmotherapy, sedation, or EVD during the challenge
• Continuous ICP and MAP monitoring required
• Record baseline and post-challenge ICP values
❤ CPP Optimization

• Based on MAP Challenge result, individualize CPP target

• If sPAR intact: may benefit from higher CPP target (up to 70–80 mmHg)

• If sPAR impaired: avoid pushing CPP above 70 — may worsen ICP and cause ARDS

• Use norepinephrine as first-line vasopressor for MAP support

💪 Neuromuscular Blockade (NMB) Trial

• Consider a trial dose of NMB agent to assess ICP response

• Cisatracurium 0.1–0.2 mg/kg bolus, then 1–3 mcg/kg/min infusion (preferred — organ-independent Hofmann elimination)

• Rocuronium 0.6–1.2 mg/kg bolus, then 0.3–0.6 mg/kg/hr infusion (alternative)

• Reduces ICP by eliminating shivering, coughing, and ventilator dyssynchrony

⚠ Cautions:
• Must ensure adequate sedation/analgesia first — paralysis without sedation is inhumane and undetectable
• Obscures neurological examination — limits pupil reactivity as only clinical assessment
• Increases risk of ICU-acquired weakness with prolonged use (>48h)
• Monitor with Train-of-Four (TOF) — target 1–2/4 twitches
• Increased DVT/PE risk — ensure thromboprophylaxis
Tier 3 — Rescue Therapies HIGH RISK
💥 Barbiturate Coma

Thiopental:

• Loading: 5–10 mg/kg IV slow bolus, then repeat 5 mg/kg q10min until ICP controlled or burst-suppression on EEG

• Maintenance: 3–5 mg/kg/hr continuous infusion

Pentobarbital (alternative):

• Loading: 10 mg/kg over 30 min, then 5 mg/kg/hr × 3h

• Maintenance: 1–3 mg/kg/hr, titrate to burst-suppression

Target: EEG burst-suppression (3–10 second bursts)

⚠ Critical Contraindications & Risks:
• Hemodynamic instability / Hypotension — barbiturates cause profound myocardial depression and vasodilation; requires vasopressor support in most patients
• Immunosuppression — significantly increases infection risk (pneumonia, sepsis)
• Paralytic ileus — delays enteral nutrition
• Hepatic dysfunction — prolonged elimination
• Completely abolishes neurological exam — only ICP/PbtO₂ and pupil reactivity remain assessable
• No clear mortality benefit demonstrated (Cochrane 2012) — use only as last-resort medical therapy
✅ Monitoring:
• Continuous EEG (mandatory — titrate to burst-suppression)
• Continuous arterial BP + CVP monitoring
• Serum barbiturate levels if available
• Core temperature (barbiturates cause hypothermia)
🩸 Decompressive Craniectomy (DC)

• Surgical removal of a large bone flap (≥12 × 15 cm or bifrontal) to allow brain expansion

• DECRA trial (2011): Early bifrontal DC for diffuse TBI → reduced ICP but worse functional outcomes

• RESCUEicp trial (2016): Last-resort DC → reduced mortality (26.9% vs 48.9%) but increased proportion of survivors with severe disability

• Current recommendation: Reserve for refractory ICP elevation after maximal medical therapy has failed

⚠ Relative Contraindications:
• Bilateral fixed, dilated pupils for >4 hours — suggests irreversible brainstem damage
• GCS 3 with bilateral absent pupillary reflexes
• Devastating primary brain injury incompatible with meaningful recovery
• Coagulopathy — must correct before surgery
• Shared decision-making with family is essential regarding expected outcomes
❄ Mild Hypothermia

• Target core temperature 35–36°C (mild therapeutic hypothermia)

• Reduces cerebral metabolic rate and ICP

• Eurotherm3235 trial (2015): Hypothermia (32–35°C) for ICP management → worse outcomes at 6 months. Trial stopped early.

• Current consensus: 35–36°C may be considered as rescue; avoid ≤35°C for ICP management

⚠ Risks:
• Coagulopathy — hypothermia impairs clotting cascade
• Cardiac arrhythmias — QT prolongation, bradycardia, VF risk at <32°C
• Immunosuppression / increased infection risk
• Electrolyte shifts (hypokalemia during cooling, hyperkalemia during rewarming)
• Rebound ICP elevation during rewarming — rewarm slowly (0.25°C/hr)

Clinical Assessment Summary








    
Recent Updates

    
    
        
  • The American College of Surgeons published updated TBI Best Practices Guidelines (2024), reinforcing practical bedside targets: ICP <22 mmHg, CPP 60–70 mmHg, hemoglobin transfusion threshold ≥7 g/dL, and SBP ≥110 mmHg when ICP is not monitored.
    • 
        
  • Severe-TBI care now combines the BTF 4th-edition guidelines with the SIBICC tiered algorithms; routine brain-tissue-oxygen-directed therapy and liberal transfusion thresholds remain unproven in recent trials.
    • 
    

    
American College of Surgeons Committee on Trauma. Best Practices Guidelines: The Management of Traumatic Brain Injury (2024).

    
Key Knowledge Points

    
    
        
  • Monroe-Kellie Doctrine: The skull is a rigid box containing brain (~80%), CSF (~10%), and blood (~10%). An increase in any one component must be compensated by a decrease in another, or ICP rises.
    • 
        
  • ICP threshold for treatment: Current guidelines recommend initiating ICP-lowering therapy when ICP exceeds 20–22 mmHg. Both absolute values and trends matter — a rising trajectory is more concerning than a single measurement.
    • 
        
  • CPP target 60–70 mmHg. CPP below 60 mmHg risks cerebral ischemia; above 70 mmHg, aggressive vasopressor use increases ARDS risk. The MAP Challenge in Tier 2 can help individualize the target.
    • 
        
  • HTS vs Mannitol: Hypertonic saline has a reflection coefficient of 1.0 (no BBB penetration) vs 0.9 for mannitol, resulting in less rebound ICP. HTS also maintains hemodynamic stability. Recent guidelines favor HTS, but both remain acceptable first-line agents.
    • 
        
  • Avoid hypotonic fluids. Even a single episode of hypotension (SBP <90 mmHg) doubles mortality in TBI. Use isotonic or hypertonic crystalloids exclusively.
    • 
        
  • Hyperventilation is a bridge, not a treatment. PaCO₂ 32–35 mmHg is Tier 2 only. Below 30 mmHg causes dangerous cerebral ischemia. Efficacy wanes within hours.
    • 
        
  • Steroids have NO role in TBI. The CRASH trial (10,008 patients) demonstrated increased mortality with corticosteroids in traumatic brain injury. Do not use dexamethasone for ICP in TBI. (Exception: vasogenic edema from brain tumors — dexamethasone is first-line.)
    • 
        
  • Tiered approach is essential. The SIBICC algorithm emphasizes moving from lower-risk (Tier 1) to higher-risk (Tier 3) interventions sequentially, with inter-tier reassessment for remediable causes.
    • 
    








    
About This ICP Management Guideline

    
The Intracranial Pressure (ICP) Management Guideline is an interactive clinical decision-support tool designed to guide clinicians through a structured, tiered approach to managing elevated intracranial pressure. Intracranial hypertension is a neurological emergency that can result from traumatic brain injury, intracranial hemorrhage, ischemic stroke with malignant edema, CNS infections, hepatic encephalopathy, and brain tumors. Untreated, it leads to cerebral herniation and death. This ICP management guideline integrates the latest evidence from the Brain Trauma Foundation (BTF) 4th edition, the Seattle International Severe TBI Consensus Conference (SIBICC) algorithm, the ACS TBI 2024 best practices, and the Neurocritical Care Society (NCS) 2020 cerebral edema guidelines. It provides a comprehensive protocol spanning from baseline neuroprotective measures (Tier 0) through first-line osmotherapy with dose calculations (Tier 1), second-line interventions such as hyperventilation and MAP Challenge (Tier 2), to rescue therapies including barbiturate coma and decompressive craniectomy (Tier 3).


    
How to Use This Guideline

    
Step 1 — Enter Patient Weight: Use the digit buttons to enter the patient’s body weight in kilograms. This is used to calculate weight-based osmotherapy doses for mannitol, 3% NaCl, and glycerol.

    
Step 2 — Select Management Tier: Click on the appropriate tier based on the clinical situation. Tier 0 should be initiated for all patients with suspected or confirmed intracranial hypertension. Progress to higher tiers only when lower-tier interventions fail to control ICP.

    
Step 3 — Osmotherapy Selection (Tier 1): Click on the specific osmotherapy agent to view its dosing, contraindications, and monitoring requirements. The calculator automatically computes weight-based doses. Review all contraindications before administering any agent.

    
Step 4 — Clinical Assessment Summary: After selecting a tier and osmotherapy agent, a summary is generated that can be copied into the EMR progress note for documentation.

    
General Principle: Always address Tier 0 baseline measures first. The tiered approach is sequential — do not skip to higher tiers without exhausting lower tiers, and reassess the patient for remediable causes when advancing between tiers.


    
Clinical Interpretation & Limitations

    
This ICP management guideline is based on the SIBICC consensus algorithm (class III evidence), the BTF 4th edition guidelines, and the most recent published reviews and meta-analyses through 2025. The tiered framework reflects combined expert opinion from 42 internationally recognized TBI specialists and should be used as a guide, not a rigid protocol.

    
Key limitations:

    
    
        
  • The SIBICC algorithm was designed primarily for severe TBI with ICP monitors in place. Adaptation to other etiologies (stroke, hepatic failure, CNS infection) requires additional clinical judgment.
    • 
        
  • Optimal osmotherapy agent (mannitol vs HTS) remains debated. Most meta-analyses show comparable efficacy at equimolar doses, with HTS potentially preferred in hypovolemic patients.
    • 
        
  • Individual patient factors (age, comorbidities, injury severity, autoregulation status) must always guide decision-making beyond algorithmic recommendations.
    • 
        
  • Barbiturate coma and decompressive craniectomy have no proven mortality benefit with good functional outcomes — the decision to pursue Tier 3 therapies requires careful shared decision-making with patients’ families.
    • 
        
  • This tool does not replace ICP monitoring. Clinical signs of herniation (pupil dilation, posturing, Cushing response) should prompt immediate treatment regardless of tier positioning.
    • 
    


    
Frequently Asked Questions (FAQ)


    
Q1. When should ICP-lowering treatment be initiated?

    
Current guidelines recommend initiating treatment when intracranial pressure exceeds 20–22 mmHg. The BTF 4th edition uses a threshold of 22 mmHg, while the SIBICC algorithm uses 20 mmHg. In practice, a combination of ICP values, ICP waveform morphology, clinical examination (pupil changes, motor deterioration), and brain CT findings should guide the decision to treat. Treatment should not be delayed in patients showing clinical signs of herniation, even if a specific ICP value has not been measured.


    
Q2. Should I use mannitol or hypertonic saline for elevated ICP?

    
Both are effective first-line osmotherapy agents with comparable ICP-lowering efficacy at equimolar doses. Hypertonic saline has theoretical advantages: a higher osmotic reflection coefficient (1.0 vs 0.9), no diuretic effect (preserving hemodynamic stability and CPP), and lower risk of rebound ICP elevation. Recent guidelines from the NCS (2020) and ACS TBI (2024) favor hypertonic saline, particularly in hypovolemic patients. However, mannitol remains a reasonable choice and may be preferred as a bridge to emergent neurosurgery. In practice, many centers use both agents, switching to the alternative when one becomes less effective.


    
Q3. What is the target CPP in patients with elevated ICP?

    
The recommended cerebral perfusion pressure (CPP) target is 60–70 mmHg (BTF Level IIB). CPP values below 60 mmHg risk cerebral ischemia, while aggressively pushing CPP above 70 mmHg with fluids and vasopressors increases the risk of acute respiratory distress syndrome (ARDS) (BTF Level III). When ICP monitoring is unavailable, the ACS TBI 2024 guidelines recommend targeting a MAP above 80 mmHg to ensure adequate cerebral perfusion. The MAP Challenge technique in Tier 2 can help individualize the CPP target based on autoregulation status.


    
Q4. Why is prolonged hyperventilation harmful in brain injury?

    
Hyperventilation reduces intracranial pressure by causing cerebral vasoconstriction, which decreases cerebral blood volume. However, this same vasoconstriction also reduces cerebral blood flow, potentially worsening cerebral ischemia — particularly in the first 24 hours after injury when CBF is already critically reduced. Furthermore, the ICP-lowering effect of hyperventilation is only temporary (4–6 hours) because the brain’s CSF bicarbonate system compensates for the respiratory alkalosis. For these reasons, hyperventilation should only be used as a temporizing measure in Tier 2, targeting PaCO₂ of 32–35 mmHg, with monitoring of brain oxygenation (SjvO₂ or PbtO₂).


    
Q5. What are the indications for decompressive craniectomy?

    
Decompressive craniectomy is a Tier 3 rescue therapy reserved for refractory intracranial hypertension that has failed maximal medical management including Tier 1 and Tier 2 therapies. The RESCUEicp trial (2016) demonstrated that last-resort decompressive craniectomy reduces mortality compared to medical management alone (26.9% vs 48.9% at 6 months), but increases the proportion of survivors with severe disability. The DECRA trial (2011) showed that early bifrontal craniectomy for diffuse TBI reduced ICP but was associated with worse functional outcomes. Current consensus is that DC should be considered only after thoughtful shared decision-making with the family, weighing survival against quality of life.


    
Related Calculators

    

    

        
📖 Sources:

        
    
            
  1. Carney N, et al. (2017). Guidelines for the Management of Severe Traumatic Brain Injury, Fourth Edition. Neurosurgery, 80(1):6–15.
    2. 
            
  2. Hawryluk GWJ, et al. (2019). A management algorithm for patients with intracranial pressure monitoring: the SIBICC. Intensive Care Med, 45:1783–1794.
    3. 
            
  3. Chesnut R, et al. (2020). A management algorithm for adult patients with both brain oxygen and intracranial pressure monitoring: the SIBICC. Intensive Care Med, 46(5):919–929. PMID: 31965267.
    4. 
            
  4. Cook AM, et al. (2020). Guidelines for the Acute Treatment of Cerebral Edema in Neurocritical Care Patients. Neurocrit Care, 32:647–666.
    5. 
            
  5. American College of Surgeons. (2024). Best Practices Guidelines: Management of Traumatic Brain Injury.
    6. 
            
  6. Viarasilpa T. (2024). Managing Intracranial Pressure Crisis. Curr Neurol Neurosci Rep, 25:12. PMID: 39699775.
    7. 
            
  7. Bianchini L, et al. (2025). Management of intracranial hypertension with and without invasive ICP monitoring. World J Crit Care Med, 14(3):105645. PMID: 40880574.
    8. 
            
  8. Rapp A, Kobeissi H, Fahim DK. (2025). Updated Review of the Management of and Guidelines for Traumatic Brain Injury. Journal of Clinical Medicine, 14(19):6796. PMID: 41095876.
    9. 
        

    


    

        
⚠️ Disclaimer:

        
This tool is for informational and educational purposes only and is not a substitute for professional clinical judgment. All treatment decisions must be made by a qualified healthcare professional considering the individual patient’s full clinical context. Intracranial pressure management requires real-time monitoring and individualized decision-making that no algorithm can fully replace.

    






    DosePilot Logo
    
Powered by DosePilot.com